医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CHA Medical & Bio Group Announces Groundbreaking for its New Cell Gene Biobank Facility

2022年03月31日 AM12:00
このエントリーをはてなブックマークに追加


 

PANGYO, South Korea

CHA Medical & Bio Group officially began construction of its Cell Gene Biobank (CGB) facility in Pangyo, South Korea. Investing over $250 million in the project, the new 710,000 ft2 site will comprise one of the world’s largest single facilities for cell and gene therapy manufacturing and advanced stem cell biobanking. The construction of the state-of-art facility is expected to be completed by the end of 2024.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220330005635/en/

Han Joong Kim, President of CHA Medical & Bio Group (10th from the left), Ganglip Kim, head of the Ministry of Food and Drug Safety (9th from the left) and other officials break ground on Cell Gene Biobank groundbreaking ceremony. (Photo: Business Wire)

Han Joong Kim, President of CHA Medical & Bio Group (10th from the left), Ganglip Kim, head of the Ministry of Food and Drug Safety (9th from the left) and other officials break ground on Cell Gene Biobank groundbreaking ceremony. (Photo: Business Wire)

Within the facility, the space dedicated for cell and gene therapy will offer integrated CDMO services for mRNA, viral vectors, and plasmid DNA, providing GMP production with multiple segregated cleanrooms to deliver greater manufacturing efficiency. The stem cell biobank will be designed to store various cell types including stem cells, NK cells, cord blood, sperm cells, and egg cells.

At its new CGB facility, CHA Medical & Bio Group will integrate its proprietary cell separation, cell culture, and cryopreservation technologies with its wide range of services to provide more optimized and customized approaches to cell and gene therapy development.

“Cell and gene therapy development and production requires extensive expertise and highly specialized equipment when compared to other biologics with more established manufacturing processes, such as antibodies,” said Dr. Kwang Yul Cha, the global research and innovation leader at CHA Medical & Bio Group. He further mentioned that “we believe that this CGB will function as the leading cell and gene therapy manufacturing hub of Asia, incorporating CHA Biotech’s long history and in-depth knowledge of cell therapy R&D and manufacturing process technology.”

Upon its completion, CGB will act as a key growth engine of CHA Medical & Bio Group’s CDMO business. Together with Matica Biotechnology, Inc., the company’s affiliate cell and gene therapy expert CDMO in the U.S., CHA Medical & Bio Group aims to establish a differentiated strategy for building a strong, global CDMO network.

About CHA Medical & Bio Group

CHA Medical & Bio Group is world leading healthcare enterprise in Korea. It operates multiple medical centers, more than 48 affiliate companies and CHA university. CHA Medical & Bio Group is currently expanding its business into cell and gene therapies, aiming to contribute to health of the entire global community through substantial research and innovation in biotechnology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220330005635/en/

CONTACT

Young-Ho Yi

Manager / Public Relations Team

CHA Bio Group

nayyh95@chamc.co.kr

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 《新英格兰医学杂志》发表Fazirsiran治疗α-1抗胰蛋白酶缺乏症患者的二期研究结果
  • Twist Bioscience and Ildong Pharmaceutical Enter into a Collaboration to Enhance Antibody Discovery for Applications in Immuno-oncology
  • 沃博联结束战略评估,决定保留表现优异的博姿业务
  • BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
  • Work for Humankind:联想技术为偏远岛屿开启无限可能